|Friday, 13 May 2011 07:35|
Based in San Diego, California, this new company aims to improve the quality and priligy dapoxetine performance of treatments for patients with all types of solid tumor cancers using "Precision Tumor Destruction" by using a combination of hardware and buy cialis cheap drugs (electro-chemical tumor ablation and can you buy nexium over the counter electro-immunotherapy with DNA based cytokines).
I ran into Dr. Dhillon at the recent Roth Investment Conference in Southern California and buy doxycycline for dogs some of the results for his platform were impressive, particularly since the technology has already shown efficacy and strong safety profile in 400+ patients during clinical trials involving cutaneous (BCC, SCC, melanoma), head & neck, breast, prostate, and pancreatic tumors.
OncoSec's innovative research and priligy results the advancement of a new “electro-oncology” therapy has obviously started to gain the attention of early investors as well. Shares of the company rose 4.14% on Thursday, after we told our premium subscribers about it first. In addition, this week the company announced the appointment of three members to its leadership team and while most of the markets were down, their stock continued to climb- albeit modestly. Not bad for a company whose name is not yet widely known.
Formed earlier this year, OncoSec expects to initiate Phase II clinical trials for its tumor-destroying, tissue-sparing ElectroOncology therapies before the end of this year and we recommend that you watchlist the stock and learn more about their very interesting approach to selective killing of cancer cells while preserving healthy tissue.
The technology enters the biotech trading space at Phase II for several cancer indications based on positive Phase I clinical data. Unlike other recently introduced biotech plays, the science has notched some early victories in the pipeline process, so some of the inherently early risk is off the table.
The share structure and early valuation pricing also appears to point towards the possibility of a faster than normal uplisting to a larger exchange. Such a move would be welcome by institutions and funds already familiar with Dr. Dhillon's leadership track record who might want to also invest in his new venture.Some select slides from their investor presentation can be found below (click to enlarge).
Disclosure: No Positions